A drug-delivery device expert shares how advances in technology, digital health, and data protection could help patients better manage their drug regimens.
Ernst & Young resigned as MiMedx's outside auditor after advising the company that the internal controls necessary for MiMedx to develop reliable financial statements do not exist.
The EU regulation may have been around for more than a decade, but there is still a lot for medtech to learn.
An industry expert shares how emerging micro and nanotechnologies could shape the next generation of implantable drug-delivery systems.
From 2015 through 2018, about 20% of 510(k) clearances were based on substantial equivalence to a predicate device that was more than a decade old. Should FDA continue to allow this practice, or should older devices be retired as predicates?
Right now we’re in the middle of the Artificial Intelligence Renaissance for medtech. But what does this mean for companies? Is this a fad or is AI here to stay in medtech. MD+DI Managing Editor Omar Ford gives his thoughts on this emerging trend.
Doctors need more tools to quickly determine whether an antibiotic is truly needed, an expert tells MD+DI.
One year into the transition periods for the new EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), industry experts continue to express concern that more progress is needed to help companies prepare for the new regulations within the limited transition period.
Using VR during usability testing enables real-time design iteration in response to user feedback without the need to travel.
A presentation at the upcoming BIOMEDevice San Jose show will cover issues in connectivity for this growing segment of the medical device industry.